Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ranjit Banwait

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cureus|March 24, 2021
Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19)Ranjit Banwait, Devina Singh, Anamarys Blanco, et al.
International Journal of Emergency Medicine|November 7, 2021
Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USAVaibhav Rastogi, Ranjit Banwait, Devina Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemiaXavier Leleu, Wanling Xie, Meghan Bagshaw, et al.
American Journal of Hematology|June 18, 2011
The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemiaRanjit Banwait, Kevin O'Regan, Federico Campigotto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2012
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemiaAldo M Roccaro, Antonio Sacco, Xiaojing Jia, et al.
International Journal of Cancer|April 15, 2025
Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumorsRanjit Banwait, Heidi Ko, Joel Michalek, et al.
American Journal of Hematology|October 29, 2014
Extramedullary Waldenström macroglobulinemiaRanjit Banwait, Yosra Aljawai, Joseph Cappuccio, et al.
Blood|January 5, 2013
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemiaIrene M Ghobrial, Federico Campigotto, Timothy J Murphy, et al.
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cureus|March 24, 2021
Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19)Ranjit Banwait, Devina Singh, Anamarys Blanco, et al.
International Journal of Emergency Medicine|November 7, 2021
Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USAVaibhav Rastogi, Ranjit Banwait, Devina Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemiaXavier Leleu, Wanling Xie, Meghan Bagshaw, et al.
American Journal of Hematology|June 18, 2011
The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemiaRanjit Banwait, Kevin O'Regan, Federico Campigotto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2012
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemiaAldo M Roccaro, Antonio Sacco, Xiaojing Jia, et al.
International Journal of Cancer|April 15, 2025
Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumorsRanjit Banwait, Heidi Ko, Joel Michalek, et al.
American Journal of Hematology|October 29, 2014
Extramedullary Waldenström macroglobulinemiaRanjit Banwait, Yosra Aljawai, Joseph Cappuccio, et al.
Blood|January 5, 2013
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemiaIrene M Ghobrial, Federico Campigotto, Timothy J Murphy, et al.
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
Pageof 1